meta
|
evidence
oncology
Living systematic review and meta-analysis
RET gene alteration defined cancer
2
glioblastoma (GB)
1
<span style="margin-left: 0em;">gene alteration target therapy</span>
<span style="margin-left: 1em;">RET gene alteration targeted therapy</span>
<span style="margin-left: 2em;">pralsetinib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 2em;">selpercatinib <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
<span style="margin-left: 0em;">non active control</span>
<span style="margin-left: 1em;">no control (uncontrolled study) <i class='fa fa-circle' style='color: royalblue; font-size: 10px;'></i></span>
Select endpoint...
objective responses (ORR) (4)
DOR (2)
study list
mapping
overview
meta-analysis
forest plot
NMA
excluded
insufficient data
Evidence network for EEEE
no control (uncontrolled study)
pralsetinib
selpercatinib
direct evidence
network meta-analysis
comet plot
result box
odds ratio
A
B
0.5
1.5
1.0
odds ratio for A vs. B
and half 95% CI
T
vs.
C
no control (uncontrolled study)
pralsetinib
selpercatinib
no control (uncontrolled study)
---
NA
NA
pralsetinib
NA
---
NA
selpercatinib
NA
NA
---
pathologies: 345 - treatments: 1385
result logic
×
Study list
